Pro-Pharmaceuticals Appoints Noted Pioneer in Liver Diseases, Scott L. Friedman, M.D., to Scientific Advisory Board
10 Juli 2008 - 1:00PM
Business Wire
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a company developing
proprietary carbohydrate-based therapeutic compounds to treat
serious diseases such as cancer and fibrosis, has named Scott L.
Friedman, M.D., to its Scientific Advisory Board. Dr. Friedman,
Fishberg Professor of Medicine and Chief of the Division of Liver
Diseases at Mount Sinai School of Medicine in New York, has
performed pioneering research into the underlying causes of
scarring, or fibrosis, associated with chronic liver disease, by
characterizing the key fibrogenic cell type, the hepatic stellate
cell. He and his team are also responsible for the discovery of a
novel tumor suppressor gene, KLF6 that is inactivated in a number
of human cancers, including primary liver cancer. �There are
currently no approved anti-fibrotic treatments for patients with
liver disease. The area of anti-fibrotics is generating great
interest based on their potential to impact chronic liver disease
and I look forward to working with Pro-Pharmaceuticals to help
develop their promising compounds,� said Dr. Scott L. Friedman. �We
are delighted to welcome Dr. Friedman to our Scientific Advisory
Board, as he brings a wealth of experience in liver disease,
notable credentials and shares our commitment to developing a new
generation of liver fibrosis treatments.� said David Platt, Ph.D.,
chief executive officer of Pro-Pharmaceuticals, Inc. �Our fibrosis
compounds reduced collagen expression and caused the regression of
liver fibrosis in animal models. Collaborating with Dr. Friedman
will indeed bring us closer to the development of a new paradigm in
treating liver fibrosis.� In 2006, Pro-Pharmaceuticals entered into
a research collaboration with Mount Sinai School of Medicine to
evaluate the anti-fibrotic effects of the Company�s novel,
carbohydrate compounds. Mount Sinai has one of the world�s largest,
most productive and well-respected liver programs. Mount Sinai and
Hepatic Fibrosis A unique program, under the direction of Dr. Scott
Friedman, the Division Director of Liver Diseases and a world
authority on liver fibrosis, has been established to facilitate the
development of novel diagnostic methods and treatments of liver
fibrosis. In partnership with key pharmaceutical companies, Dr.
Friedman and his group monitor the development and testing of
potential anti-fibrotic compounds in cultured cells, in animal
models of hepatic fibrosis, and in clinical trials of patients with
chronic liver disease. All chronic liver diseases can cause
fibrosis, or scarring. Fibrosis is the reason patients with liver
disease develop liver failure and may need transplantation. Thus,
efforts to stop fibrosis may prevent complications of all chronic
liver diseases, thereby avoiding the need for transplantation.
Currently more than four million people in the U.S. have Hepatitis
C Virus, and many will develop severe fibrosis and liver failure
over the next two decades. Mount Sinai is at the forefront of liver
fibrosis research. Dr. Friedman has assembled a world-class team
who together are exploring the fundamental mechanisms underlying
liver fibrosis or scarring. From these basic investigations have
begun to emerge major new insights into how this fibrosis can be
stopped. Molecular Regulation of Hepatic Fibrosis Dr. Friedman�s
work explores the molecular mechanisms of wound healing and liver
fibrosis. He uses a variety of animal and cell culture models to
identify key inflammatory mediators and signaling molecules
regulating the activation of hepatic stellate cells, the principle
fibrogenic cells in the liver. Additionally, he tests anti-fibrotic
lead compounds to develop potential new therapies for patients with
chronic fibrosing liver diseases. Dr. Scott Friedman, Professor,
Medicine/ Liver Diseases Dr. Friedman has performed pioneering
research into the underlying causes of scarring, or fibrosis
associated with chronic liver disease, which affects millions
worldwide. Dr. Friedman was the first to isolate and characterize
the hepatic stellate cell, which is the key cell type responsible
for scar production in liver. This work followed from earlier
studies by Drs. Hans Popper and Fenton Schaffner of Mount Sinai who
emphasized the stellate cell's potential importance in liver
disease. Liver fibrosis has assumed major importance as a potential
treatment target for the millions of patients infected with
Hepatitis C, and much of this excitement can be traced to Dr.
Friedman's contributions. His work has been continuously funded by
the NIH since 1985, in addition to grants from the American Heart
Association and the American Gastroenterological Association. Dr.
Friedman is a graduate of Mount Sinai School of Medicine, where he
served as the President of Alpha Omega Alpha Honor Society and was
an awardee of the Arthur Aufses, Sr. Prize in Surgery. Dr. Friedman
was a Medical Resident at the Beth Israel Hospital, Harvard Medical
School, Boston, then a Gastroenterology Fellow at University of
California San Francisco before assuming a faculty position there
which he held for ten years. During a sabbatical from UCSF, he was
a Fulbright Scholar and Visiting Professor at the Weizmann
Institute of Science in Israel, in the laboratory of Dr. Moshe
Oren. In 2003, Dr. Friedman was awarded the Hans Popper
International Liver Research Prize, recognizing his pioneering work
into mechanisms and treatments of hepatic fibrosis. About
Pro-Pharmaceuticals Fibrosis Compounds Pro-Pharmaceuticals is
developing a series of novel carbohydrate compounds that reduced
collagen expression and caused the regression of liver fibrosis in
animal models. Uncontrolled collagen expression is a pathological
process that occurs during the fibrotic process, affecting various
organs and leads to scar tissue. Chemical toxicity, microbial
infection or physical injury cause hepatic, renal, cardiac and
pulmonary fibrosis. Carbohydrate polymers were synthesized and
screened to inhibit collagen production in in-vivo and in-vitro
fibrosis models. The Company is collaborating with Mount Sinai
School of Medicine in New York to evaluate the anti-fibrotic
effects of the Company�s carbohydrate compounds on liver fibrosis.
The Company also entered into a research collaboration with The
Brigham and Women�s Hospital to evaluate the anti-fibrotic effects
of the Company�s novel, carbohydrate compounds to treat acute and
chronic kidney disease. Brigham and Women�s Hospital is one of the
largest, most respected research hospitals in the country.
According to the National Kidney Foundation, approximately 12
million people suffer from kidney fibrosis. About
Pro-Pharmaceuticals, Inc. � Advancing Drugs Through Glycoscience�
Pro-Pharmaceuticals is a clinical stage pharmaceutical company
engaged in the discovery, development and commercialization of
carbohydrate-based, target therapeutic compounds for advanced
treatment of cancer, liver, microbial and inflammatory diseases.
The Company�s initial focus is the development of carbohydrate
polymers to treat cancer patients. DAVANAT�, the Company�s lead
product candidate, is a polysaccharide polymer that is in Phase II
trials for colorectal and biliary cancer. The Company�s technology
is also being used to develop new chemical entities to treat liver
and kidney fibrosis. The Company is headquartered in Newton, Mass.
Additional information is available at www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release
about future expectations, plans and prospects for the Company,
including without limitation statements containing the words
"believes," "anticipates," "plans," "expects," and similar
expressions, constitute forward-looking statements as defined in
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
management's current expectations and are subject to a number of
factors and uncertainties, which could cause actual results to
differ materially from those described in such statements. We
caution investors that actual results or business conditions may
differ materially from those projected or suggested in
forward-looking statements as a result of various factors
including, but not limited to, the following: uncertainties as to
the utility and market for our potential products; uncertainties
associated with pre-clinical and clinical trials of our product
candidates. More information about those risks and uncertainties is
contained in the Company's most recent quarterly or annual report
and in the Company's other reports filed with the Securities and
Exchange Commission. While the Company anticipates that subsequent
events may cause the Company's views to change, the Company
disclaims any obligation to update such forward-looking statements.
DAVANAT and Advancing Drugs Through Glycoscience are registered
trademarks of Pro-Pharmaceuticals.
Pro (AMEX:PRW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pro (AMEX:PRW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024